Citadel Advisors
INBX icon

Citadel Advisors’s Inhibrx INBX Stock Holding History

Citadel Advisors’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.53M Buy
37,300
+2,900
+8% +$291K ﹤0.01% 5362
2026
Q1 		$2.31M Sell
34,400
-9,400
-21% -$697K ﹤0.01% 5784
2025
Q4 		$3.46M Buy
+43,800
New +$2.98M ﹤0.01% 4900
2025
Q2 		– Sell
-35,500
Closed -$497K – 13727
2025
Q1 		$497K Buy
35,500
+775
+2% +$10.5K ﹤0.01% 8492
2024
Q4 		$535K Sell
34,725
-13,850
-29% -$211K ﹤0.01% 8399
2024
Q3 		$761K Buy
+48,575
New +$683K ﹤0.01% 7391

Other funds holding INBX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors's INBX Position: Q2 2026 in Review

Citadel Advisors sold out of Inhibrx (INBX) in Q2 2026, closing a stake of 33,157 shares — an estimated $3.32M sold.

Citadel Advisors first reported a position in INBX in Q3 2025 and held it in 3 quarters. The position peaked at $2.23M in Q1 2026. 162 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

  • Citadel Advisors reported no remaining Inhibrx position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 33,157 Inhibrx shares in Q2 2026, an estimated $3.32M.
  • Citadel Advisors first reported a position in Inhibrx in Q3 2025 and held it in 3 quarters.
  • Citadel Advisors's Inhibrx position peaked at $2.23M in Q1 2026.
  • 162 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.